Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at about $10 billion equity value ($8.8 billion net of cash).

Vertex says the acquisition is a strategic move to build an endocrinology franchise and expects to close in Q3 2026 .

The deal centers on two endocrine assets Vertex believes could top $5 billion in combined peak annual sales: PALSONIFY , an approved once-daily oral therapy for acromegaly, and atumelnant , a late-stage treatment for congenital adrenal hyperplasia (CAH).

Vertex highlighted strong early PALSONIFY uptake and payer coverage progress.

Vertex plans to finance the purchase with cash and debt, including $4.5 billion in committed bridge financing.

Management said the acquisition should have only a modest near-term financial impact and become accretive to non-GAAP operating income by 2029 , while noting some development and safety risks remain for atumelnant.

Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.

On a conference call announcing the deal, Vertex CEO and President Dr. Reshma Kewalramani said the transaction has a total equity value of about $10 billion, or $8.8 billion net of estimated cash acquired.

She said Crinetics brings two lead endocrine assets that Vertex believes could generate more than $5 billion in combined peak annual sales: PALSONIFY, an approved oral therapy for acromegaly, and atumelnant, an investigational therapy in pivotal development for congenital adrenal hyp...